Parker Institute for Cancer Immunotherapy

Developers of programmable CAR T therapies and human-compatible organs for transplantation garner nine-figure fundings

Plus: Madrigal hires Shannon Kelley as general counsel, and updates from NodThera, Dragonfly, AusBiotech and more

Letter requesting FBI, intel briefings suggests aperture is widening from CROs and security to therapeutic developers and commercial competitiveness

Xaira will initially aim Baker tech at validated targets; functional genomics and patient data are its plan for “breaking the system” for target discovery

Plus rounds for Rubedo, Flindr, Endeavor, SynOx and more

Early 2024 dealmaking activity also included Roche-MOMA, Avenzo-Allorion, AbbVie-Umoja and Boehringer-3T

Plus: Venture cash for ADARx, Georgiamune, Neurophth and updates from Regeneron-Decibel, Novartis, Sunbird-Glympse, Denali-Takeda and more

How the Stanford professor and serial entrepreneur thinks about the academia-industry interface, pediatric programs and triaging innovations

Plus: GSK licenses WuXi Biologics bispecific, Acelyrin adds thyroid eye asset via ValenzaBio takeout, HighTide, Metagenomi, Synaffix-Amgen, AstraZeneca and more

Cell therapy business adds armored CAR T platform, handful of therapies, but won’t advance prostate cancer program